Devonian Health Group Inc (OTCMKTS:DVHGF) Stock Takes a Hit: Here is Why

Late stage clinical biopharmaceutical firm Devonian Health Group Inc (OTCMKTS:DVHGF) is involved with the development of a novel portfolio of cosmeceutical and pharmaceutical products. The company was in the news cycle last Friday after it announced that it had appointed three new independent directors to its board of directors.

Trading Data

On Friday, DVHGF stock ended flat at $0.1743 with more than 10K shares, compared to its average volume of 0 shares. The stock moved within a range of $0.1743 – 0.1743 after opening trading at $0.1743.

Devonian Health Group Announces the Appointment of New Board Members and Grant of Stock Options

The three new directors were Jean Forcione, David Baker and Edouard Dahl. Additionally the company also announced that it had granted options to its consultants and directors. The Chief Executive Officer and President of the company Pierre J Montanaro spoke about the latest development as well.

He commented that everyone at the company was pleased at the fact that Devonian Health Group had welcomed new members in its board of directors. He added that he was also looking forward to the contributions that were going to be made by the three new independent directors towards the growth of the company.

David Baker is a biotech industry veteran and has worked in the sector for more than three decades. Edouard Dahl is a retired pharmaceutical executive with more than 30 years of experience across many business verticals. Jean Forcione has experience spanning 35 years in the healthcare space and has worked in a range of niches.